StockDriftsStockDriftsTop 3 Rivervest Venture Management Llc Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| RPHM | Reneo Pharmaceuticals, Inc. | 63% | 2.53M | $4.3M | +0.00%(+0) | — | 2024-09-30 | |
| SPRB | Spruce Bioscience, Inc. | 20.39% | 2.94M | $1.4M | +0.00%(+0) | — | 2024-09-30 | |
| XLO | Xilio Therapeutics, Inc. | 16.6% | 1.44M | $1.1M | +0.00%(+0) | — | 2024-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — |
| Top 20 Holdings Unweighted | — | — | — | — |
Rivervest Venture Management Llc reports $6.84M in US-listed equity holdings across 3 positions in its most recent 13F filing. Its largest disclosed positions are RPHM (63.0%), SPRB (20.4%) and XLO (16.6%). Figures reflect the Q3 2024 filing.
Sign up free to track Rivervest Venture Management Llc, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Rivervest Venture Management Llc’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1812549). View Rivervest Venture Management Llc’s 13F filings on SEC